AQR Capital Management - EMERGENT BIOSOLUTIONS INC ownership

EMERGENT BIOSOLUTIONS INC's ticker is EBS and the CUSIP is 29089Q105. A total of 275 filers reported holding EMERGENT BIOSOLUTIONS INC in Q3 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.

Quarter-by-quarter ownership
AQR Capital Management ownership history of EMERGENT BIOSOLUTIONS INC
ValueSharesWeighting
Q3 2023$605,419
-20.1%
179,118
+73.7%
0.00%
-50.0%
Q2 2023$757,866
-62.8%
103,111
-49.1%
0.00%
-50.0%
Q1 2023$2,038,359
-68.3%
202,419
-63.1%
0.00%
-73.3%
Q4 2022$6,430,277
+22.1%
549,127
+118.9%
0.02%
+15.4%
Q3 2022$5,266,000
+51.5%
250,874
+118.8%
0.01%
+62.5%
Q2 2022$3,475,000
-1.5%
114,639
+33.4%
0.01%
+14.3%
Q1 2022$3,529,000
-83.6%
85,951
-82.7%
0.01%
-82.1%
Q4 2021$21,539,000
+18.5%
495,500
+36.5%
0.04%
+14.7%
Q3 2021$18,181,000
-57.2%
363,113
-46.1%
0.03%
-53.4%
Q2 2021$42,473,000
+25.5%
674,279
+83.8%
0.07%
+32.7%
Q1 2021$33,844,000
+107.4%
366,834
+101.5%
0.06%
+89.7%
Q4 2020$16,315,000
+197.8%
182,088
+243.5%
0.03%
+222.2%
Q3 2020$5,478,000
-6.2%
53,014
-28.2%
0.01%0.0%
Q2 2020$5,839,000
+38.6%
73,831
+1.4%
0.01%
+28.6%
Q1 2020$4,214,000
-18.6%
72,825
-24.1%
0.01%
+16.7%
Q4 2019$5,177,000
-23.3%
95,953
-25.7%
0.01%
-25.0%
Q3 2019$6,748,000
-24.9%
129,066
-30.6%
0.01%
-20.0%
Q2 2019$8,990,000
-31.5%
186,092
-28.4%
0.01%
-28.6%
Q1 2019$13,130,000
-20.7%
259,892
-6.9%
0.01%
-26.3%
Q4 2018$16,550,000
-6.8%
279,176
+3.5%
0.02%
+11.8%
Q3 2018$17,757,000
+27.0%
269,746
-2.6%
0.02%
+21.4%
Q2 2018$13,982,000
-21.8%
276,936
-18.4%
0.01%
-26.3%
Q1 2018$17,870,000
+15.0%
339,402
+1.5%
0.02%
+18.8%
Q4 2017$15,544,000
+44.2%
334,484
+25.5%
0.02%
+23.1%
Q3 2017$10,777,000
+166.0%
266,434
+123.0%
0.01%
+160.0%
Q2 2017$4,052,000
-7.5%
119,489
-20.8%
0.01%
-16.7%
Q1 2017$4,381,000
-30.4%
150,856
-21.3%
0.01%
-33.3%
Q4 2016$6,299,000
-2.7%
191,801
-6.6%
0.01%
-10.0%
Q3 2016$6,471,000
+100.5%
205,245
+78.9%
0.01%
+66.7%
Q2 2016$3,227,000
-32.3%
114,751
-12.5%
0.01%
-33.3%
Q1 2016$4,767,000
-50.6%
131,139
-45.6%
0.01%
-47.1%
Q4 2015$9,648,000
+42.3%
241,154
+1.4%
0.02%
+21.4%
Q3 2015$6,779,000
-29.4%
237,941
-18.3%
0.01%
-26.3%
Q2 2015$9,600,000
+16.8%
291,368
+2.0%
0.02%0.0%
Q1 2015$8,219,000
+12.4%
285,765
+6.4%
0.02%
+26.7%
Q4 2014$7,310,000
+24.0%
268,463
-3.0%
0.02%
-6.2%
Q3 2014$5,895,000
-30.5%
276,636
-26.8%
0.02%
-30.4%
Q2 2014$8,484,000
-26.3%
377,736
-17.0%
0.02%
-34.3%
Q1 2014$11,506,000
+5.1%
455,336
-4.4%
0.04%
+6.1%
Q4 2013$10,951,000
+19.4%
476,336
-1.1%
0.03%
+3.1%
Q3 2013$9,175,000
+21.9%
481,636
-7.7%
0.03%
+18.5%
Q2 2013$7,527,000
+79.3%
522,001
+99.4%
0.03%
+50.0%
Q4 2012$4,199,000261,8010.02%
Other shareholders
EMERGENT BIOSOLUTIONS INC shareholders Q3 2021
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 1,031,859$59,703,0003.40%
Laurus Investment Counsel Inc. 74,169$4,291,0003.10%
Hillcrest Asset Management LLC 220,660$12,767,0003.07%
RICE HALL JAMES & ASSOCIATES, LLC 765,202$44,275,0002.47%
Tygh Capital Management, Inc. 142,732$8,258,0001.85%
EARNEST PARTNERS LLC 2,782,776$161,011,0001.81%
Pier Capital, LLC 93,603$5,416,0001.20%
Portolan Capital Management 131,659$7,618,0001.14%
Phocas Financial Corp. 92,759$5,367,0001.08%
Consolidated Investment Group LLC 37,000$2,141,0000.94%
View complete list of EMERGENT BIOSOLUTIONS INC shareholders